A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.
The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
The division cycle of eukaryotic cells is regulated by a family of protein kinases known as the cyclin-dependent kinases (CDKs). The sequential activation of individual members of this family and their consequent phosphorylation of critical substrates promotes orderly progression through the cell cycle. The complexes formed by CDK4 and the D-type cyclins have been strongly implicated in the control of cell proliferation during the G1 phase. CDK4 exists, in part, as a multi-protein complex with a D-type cyclin, proliferating cell nuclear antigen and a protein, p21 (refs 7-9). CDK4 associates separately with a protein of M(r) 16K, particularly in cells lacking a functional retinoblastoma protein. Here we report the isolation of a human p16 complementary DNA and demonstrate that p16 binds to CDK4 and inhibits the catalytic activity of the CDK4/cyclin D enzymes. p16 seems to act in a regulatory feedback circuit with CDK4, D-type cyclins and retinoblastoma protein.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“p16, on the other hand, acts through the Retinoblastoma (Rb) pathway (Serrano et al, 1993).”
From Distinct senotypes in p16- and p21-positive cells across human and mouse aging tissues (2025) · cites this paper as Serrano et al, 1993
In the citing paper
“p16INK4A is a 16 KDa protein that directly binds to CDK4/6 and blocks the formation of cyclinD-CDK4/6 complexes, thereby preventing phosphorylation of RB and promoting expression of E2F target genes (Serrano et al., 1993).”
From Mechanisms of Cellular Senescence: Cell Cycle Arrest and Senescence Associated Secretory Phenotype (2021) · cites this paper as Serrano et al., 1993
In the citing paper
“This member of the INK4a family is a cyclin D-dependent kinase CDK4 and CDK6 inhibitor, which prevents the phosphorylation of the retinoblastoma protein (Rb), therefore leading to suspension of the cell cycle before the S-phase [78,79].”
From Ageing, Cellular Senescence and Neurodegenerative Disease (2018) · cites this paper as [78]
In the citing paper
“Currently, p16Ink4a is one of the widely used markers for studying cellular senescence, and it plays a prominent role in inhibiting CDK4/6 and restricting the progression of G1 to S phase in the cell cycle.16,17”
From Identifying specific functional roles for senescence across cell types (2024) · doi:10.1016/j.cell.2024.09.021 · cites this paper as [16]
In the citing paper
“Currently, p16Ink4a is one of the widely used markers for studying cellular senescence, and it plays a prominent role in inhibiting CDK4/6 and restricting the progression of G1 to S phase in the cell cycle.16,17”
From Identifying specific functional roles for senescence across cell types (2024) · doi:10.1016/j.cell.2024.09.021 · cites this paper as [16]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Antibodies, a laboratory manual
(1989) · Biomedicine & Pharmacotherapy · doi:10.1016/0753-3322(89)90130-3 · Cited by 12,366
A novel genetic system to detect protein–protein interactions
Fields, S., & Song, O.-K. (1989) · Nature · doi:10.1038/340245a0 · Cited by 6,114
p21 is a universal inhibitor of cyclin kinases
Xiong, Y., Hannon, G. J., Zhang, H., Casso, D., Kobayashi, R., & Beach, D. (1993) · Nature · doi:10.1038/366701a0 · Cited by 3,368
Self-citationSherr, C. J. (1993) · Cell · doi:10.1016/0092-8674(93)90636-5 · Cited by 1,960
(1993) · Genes & Development · doi:10.1101/gad.7.3.331 · Cited by 1,264
Colony-stimulating factor 1 regulates novel cyclins during the G1 phase of the cell cycle
Matsushime, H., Roussel, M. F., Ashmun, R. A., & Sherr, C. J. (1991) · Cell · doi:10.1016/0092-8674(91)90101-4 · Cited by 1,167
Xiong, Y., Zhang, H., & Beach, D. (1992) · Cell · doi:10.1016/0092-8674(92)90518-h · Cited by 1,021
Self-citationFunctional interactions of the retinoblastoma protein with mammalian D-type cyclins
Ewen, M. E., Sluss, H. K., Sherr, C. J., Matsushime, H., Kato, J.-Y., & Livingston, D. M. (1993) · Cell · doi:10.1016/0092-8674(93)90136-e · Cited by 1,010
A family of human cdc2-related protein kinases.
Meyerson, M., Enders, G. H., Wu, C. L., Su, L. K., Gorka, C., Nelson, C., Harlow, E., & Tsai, L. H. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05360.x · Cited by 923
Matsushime, H., Ewen, M. E., Strom, D. K., Kato, J.-Y., Hanks, S. K., Roussel, M. F., & Sherr, C. J. (1992) · Cell · doi:10.1016/0092-8674(92)90360-o · Cited by 897
Research works printed but not linked: 2
- Motokura, T. & Arnold, A. Biochim. biophys. Acta 1155, 63–78 (1993).
- Lukas, J., Pagano, M., Staskova, Z., Draetta, G. & Bartek, J. Oncogene (in the press).
Cited by
Items 601–700 of 1,022
Chandra, A., Lagnado, A. B., Farr, J. N., Doolittle, M., Tchkonia, T., Kirkland, J. L., LeBrasseur, N. K., Robbins, P. D., Niedernhofer, L. J., Ikeno, Y., et al. (2022) · Aging Cell · doi:10.1111/acel.13602 · Cited by 120
Noda, I., Fujieda, S., Seki, M., Tanaka, N., Sunaga, H., Ohtsubo, T., Tsuzuki, H., Fan, G., & Saitô, H. (1999) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19990118)80:2<279::aid-ijc18>3.0.co;2-n · Cited by 73
Differential gene expression in leiomyosarcoma
Skubitz, K. M., & Skubitz, A. P. N. (2003) · Cancer · doi:10.1002/cncr.11586 · Cited by 120
Hui, R., Macmillan, R. D., Kenny, F. S., Musgrove, E. A., Blamey, R. W., Nicholson, R. I., Robertson, J. F. R., & Sutherland, R. L. (2000) · PubMed · Cited by 143
Deletions of p15 and/or p16 genes as a poor-prognosis factor in adult T-cell leukemia.
Yamada, Y., Hatta, Y., Murata, K., Sugawara, K., Ikeda, S., Masanobu, M. I. N. E., Maeda, T., Hirakata, Y., Kamihira, S., Tsukasaki, K., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.5.1778 · Cited by 127
Wouters, B. G., Sy, A. M., & Skarsgard, L. D. (1996) · Radiation Research · doi:10.2307/3579302 · Cited by 121
Li, Y., Nagai, H., Ohno, T., Yuge, M., Hatano, S., Ito, E., Mori, N., Saito, H., & Kinoshita, T. (2002) · Blood · doi:10.1182/blood-2001-11-0026 · Cited by 120
“Bisulfite sequencing We modified 500 ng genomic DNA extract from clinical samples and cell lines with sodium bisulfite as described26 using a DNA modification kit (CpGenome DNA Modification Kit; Oncor, Gaithersburg, MD) according to the manufacturer’s instructions.”
MethodInfluentialHeterogeneity in intratumor distribution of p53 mutations in human prostate cancer.
Mirchandani, D., Zheng, J., Miller, G. J., Ghosh, A. K., Shibata, D. K., Côté, R. J., & Roy‐Burman, P. (1995) · Europe PMC (PubMed Central) · Cited by 120
Palafox, M., Monserrat, L., Bellet, M., Villacampa, G. J., González-Pérez, A., Oliveira, M., Brasó‐Maristany, F., Ibrahimi, N., Kannan, S., Mina, L. B., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32828-6 · Cited by 150
Modulation of Cell Growth by the Hepatitis C Virus Nonstructural Protein NS5A
Arima, N., Kao, C., Licht, T., Padmanabhan, R., Sasaguri, Y., & Padmanabhan, R. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m008329200 · Cited by 131
Eymin, B., Leduc, C., Coll, J., Brambilla, E. M., & Gazzéri, S. (2003) · Oncogene · doi:10.1038/sj.onc.1206303 · Cited by 137
“The cyclin-dependent kinase inhibitor (CDK-I) p16INK4a prevents phosphorylation and functional inactivation of the retinoblastoma (RB) protein by cyclin-dependent kinases (Serrano et al., 1993).”
BackgroundDavid, G., Grandinetti, K. B., Finnerty, P. M., Simpson, N., Chu, G. C., & DePinho, R. A. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710285105 · Cited by 119
“The role of mSin3B in cell cycle control was also examined in a setting other than growth factor regulation: p16INK4a induces growth arrest in wild-type cells through its ability to inactivate G1 cyclin-dependent kinases 4 and 6 (19).”
BackgroundThe Gene for Multiple Familial Trichoepithelioma Maps to Chromosome 9p21
Harada, H., Hashimoto, K., & Ko, M. S. H. (1996) · Journal of Investigative Dermatology · doi:10.1111/1523-1747.ep12297860 · Cited by 125
Cyclin E, a redundant cyclin in breast cancer
Gray-Bablin, J., Zalvide, J. B., Fox, M., Knickerbocker, C. J., DeCaprio, J. A., & Keyomarsi, K. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.26.15215 · Cited by 129
Loss of P16INK4 expression is frequent in high grade gliomas.
Nishikawa, R., Furnari, F. B., Lin, H., Arap, W., Berger, M. S., Cavenee, W. K., & Huang, H. (1995) · PubMed · Cited by 139
Exit from G0 and entry into the cell cycle of cells expressing p21Sdi1 antisense RNA.
Nakanishi, M., Adami, G. R., Robetorye, R. S., Noda, A., Venable, S. F., Dimitrov, D., Pereira-Smith, O. M., & Smith, J. R. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.10.4352 · Cited by 119
Walker, D., Duan, W., Popovic, E. A., Kaye, A. H., Tomlinson, F. H., & Lavin, M. F. (1995) · PubMed · Cited by 125
p27 KIP1 Blocks Cyclin E-Dependent Transactivation of Cyclin A Gene Expression
Zerfass-Thome, K., Schulze, A., Zwerschke, W., Vogt, B., Helin, K., Bartek, J., Henglein, B., & Jansen-Dürr, P. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.1.407 · Cited by 119
“inhibit cdk4 and cdk6 (14, 44), was much less active in this”
BackgroundMethodCell cycle proteins and the development of oral squamous cell carcinoma
Schoelch, M. L., Regezi, J. A., Dekker, N. P., Ng, I. O., McMillan, A., Ziober, B. L., Le, Q., Silverman, S., & Fu, K. K. (1999) · Oral Oncology · doi:10.1016/s1368-8375(98)00098-0 · Cited by 132
Alterations of the p53, p21, p16, p15 and RAS genes in childhood T-cell acute lymphoblastic leukemia
Kawamura, M., Ohnishi, H., Guo, S.-X., Sheng, X., Minegishi, M., Hanada, R., Horibe, K., Hongo, T., Kaneko, Y., Bessho, F., et al. (1999) · Leukemia Research · doi:10.1016/s0145-2126(98)00146-5 · Cited by 139
Wang, S., Ghosh, R. N., & Chellappan, S. P. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.12.7487 · Cited by 119
“Conditions that prevent the phosphorylation of Rb, including microinjection of cyclin D antibody or overexpression of the cyclin-dependent kinase (cdk) inhibitor p16, can lead to a G1 arrest (48, 68, 70, 73).”
BackgroundInactivation of P16Ink4 in Hepatocellular Carcinoma
Hui, A., Sakamoto, M., Kanai, Y., Ino, Y., Gotoh, M., Yokota, J., & Hirohashi, S. (1996) · Hepatology · doi:10.1002/hep.510240319 · Cited by 123
The great unravelling: chromatin as a modulator of the aging process
O'Sullivan, R. J., & Karlseder, J. (2012) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2012.08.001 · Cited by 116
“Epigenetic regulation of p16INK4A expression p16INK4A (also known as CDKN2a) is an important regulator in the Retinoblastoma, pRb, tumor suppressor pathway [7].”
BackgroundKamijo, T., van de Kamp, E. H., Chong, M. J., Zindy, F., Diehl, J. A., Sherr, C. J., & McKinnon, P. J. (1999) · PubMed · Cited by 140
González, M. V., Artímez, M. L., Rodrigo, L., López‐Larrea, C., Menéndez, M., Álvarez, V., Pérez, R., Fresno, M., Pérez, M. J., Sampedro, A., et al. (1997) · Journal of Clinical Pathology · doi:10.1136/jcp.50.3.212 · Cited by 117
Genomic alterations in spontaneous and carcinogen-induced murine melanoma cell lines
Melnikova, V. O., Bolshakov, S. V., Walker, C., & Ananthaswamy, H. N. (2004) · Oncogene · doi:10.1038/sj.onc.1207405 · Cited by 132
“…thus, promoting sequestration of the transcription factor E2F1 by nonphosphorylated retinoblastoma-susceptibility (pRb) tumor suppressor protein (Serrano et al., 1993; Koh et al., 1995; Lukas et al., 1995). p14ARF mediates G1 and G2 arrests by binding to human double minute protein 2 (HDM2,…”
BackgroundSuzuki, T., Narita, T., Uchida-Toita, M., & Yoshida, M. (1999) · Virology · doi:10.1006/viro.1999.9760 · Cited by 131
Isolation and characterization of p19INK4d, a p16-related inhibitor specific to CDK6 and CDK4.
Guan, K. L., Jenkins, C. W., Li, Y., O'Keefe, C. L., Noh, S., Wu, X., Zariwala, M., Matera, A. G., & Xiong, Y. (1996) · Molecular Biology of the Cell · doi:10.1091/mbc.7.1.57 · Cited by 118
Advances in the genetics of glioblastoma: are we reaching critical mass?
Purow, B. W., & Schiff, D. (2009) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.96 · Cited by 130
The Paradoxical Role of Cellular Senescence in Cancer
Yang, J., Liu, M., Hong, D., Zeng, M., & Zhang, X. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.722205 · Cited by 114
“The oncogene used in the original description of OIS is RAS; early studies have reported that expression of oncogenic RAS (HRASV12) in primary human or rodent cells causes a permanent G1 arrest and promotes premature senescence by activating p53 and p16 (Serrano et al., 1997; Lin et al., 1998).”
BackgroundHodges, A., & Smoller, B. R. (2002) · Modern Pathology · doi:10.1097/01.mp.0000032536.48264.d1 · Cited by 128
TCR Antigen–Induced Cell Death Occurs from a Late G1 Phase Cell Cycle Check Point
Lissy, N. A., van Dyk, L. F., Becker‐Hapak, M., Vocero-Akbani, A. M., Mendler, J. H., & Dowdy, S. F. (1998) · Immunity · doi:10.1016/s1074-7613(00)80458-6 · Cited by 116
Sánchez‐Beato, M., Sáez, A. I., Martínez-Montero, J. C., Mateo, M. S., Sánchez‐Verde, L., Villuendas, R., Troncone, G., & Piris, M. A. (1997) · Europe PMC (PubMed Central) · Cited by 116
Overview of high-risk HPV's 16 and 18 infected cervical cancer: Pathogenesis to prevention
Ramakrishnan, S., Partricia, S., & Ganeshan, M. (2015) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2014.12.041 · Cited by 115
Long non-coding RNAs and their implications in cancer epigenetics
Beckedorff, F., Amaral, M. S., DeOcesano-Pereira, C., & Verjovski‐Almeida, S. (2013) · Bioscience Reports · doi:10.1042/bsr20130054 · Cited by 119
Zhang, H., Chen, Z.-H., & Savarese, T. M. (1996) · Cancer Genetics and Cytogenetics · doi:10.1016/0165-4608(95)00157-3 · Cited by 125
p57Kip2 Regulates Actin Dynamics by Binding and Translocating LIM-kinase 1 to the Nucleus
Yokoo, T., Toyoshima, H., Miura, M., Wang, Y., Iida, K. T., Suzuki, H., Sone, H., Shimano, H., Gotoda, T., Nishimori, S., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m309334200 · Cited by 115
Huang, J., El‐Gamil, M., Dudley, M. E., Li, Y. F., Rosenberg, S. A., & Robbins, P. F. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.10.6057 · Cited by 127
“These two gene products regulate the cell cycle through independent means, because the p16INK4a product binds to the cyclindependent kinase 4 or 6 and cyclin D1 complex that negatively regulates progression of mammalian cells through the cell cycle (12), whereas the p14ARF product interacts with MDM2, resulting in sta…”
BackgroundCaffeine Inhibits Cell Proliferation by G0/G1 Phase Arrest in JB6 Cells
Hashimoto, T., He, Z., Ma, W.-Y., Schmid, P. C., Bode, A. M., Yang, C. S., & Dong, Z. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3453 · Cited by 115
“In particular, the cyclin D1-cdk4 complex is regulated by p16, a member of the INK4 family (25).”
BackgroundInfluentialFournel, M., Sapieha, P. S., Beaulieu, N., Besterman, J. M., & MacLeod, A. R. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.34.24250 · Cited by 132
Schwaller, J., Koeffler, H. P., Niklaus, G., Loetscher, P., Nagel, S., Fey, M., & Tobler, A. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117806 · Cited by 122
Hangaishi, A., Ogawa, S., Imamura, N., Miyawaki, S., Miura, Y., Uike, N., Shimazaki, C., Emi, N., Takeyama, K., Hirosawa, S., et al. (1996) · Blood · doi:10.1182/blood.v87.12.4949.bloodjournal87124949 · Cited by 115
Cross-talk between protein kinase C and multifunctional Ca2+/calmodulin-dependent protein kinase.
MacNicol, M., & Schulman, H. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)49824-4 · Cited by 131
Familial melanoma, pancreatic cancer and germline CDKN2A mutations
Goldstein, A. M. (2004) · Human Mutation · doi:10.1002/humu.9247 · Cited by 130
“The p16 protein inhibits the activity of the cyclin D1-cyclin-dependent kinase 4 (CDK4) or 6 (CDK6) complex (Serrano et al., 1993).”
BackgroundKourea, H. P., Cordon‐Cardo, C., Dudas, M. E., Leung, D. H. Y., & Woodruff, J. M. (1999) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)65508-3 · Cited by 117
Association of K-ras mutations with p16 methylation in human colon cancer
Guan, R. J., Fu, Y., Holt, P. R., & Pardee, A. B. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70009-0 · Cited by 151
Cellular senescence: Its role in tumor suppression and aging
Ohtani, N., Mann, D. J., & Hara, E. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01123.x · Cited by 114
Tissue-specific alternative splicing in the human INK4a/ARF cell cycle regulatory locus
Robertson, K. D., & Jones, P. A. (1999) · Oncogene · doi:10.1038/sj.onc.1202737 · Cited by 125
“Figure 3c shows that the same p12 transcript was detected only in pancreas as expected and a second band, corresponding to the size of the standard INK4a transcript (Serrano et al., 1993), was also detected.”
BackgroundInfluentialExpression of INK4 inhibitors of cyclin D-dependent kinases during mouse brain development.
Zindy, F., Soares, H. D., Herzog, K., Morgan, J., Sherr, C. J., & Roussel, M. F. (1997) · PubMed · Cited by 140
The emerging role of senescent cells in tissue homeostasis and pathophysiology
Tominaga, K. (2015) · Pathobiology of Aging & Age-related Diseases · doi:10.3402/pba.v5.27743 · Cited by 113
“and CDK4/6 activities (39), respectively, and result in the”
BackgroundSquamous Vulvar Intraepithelial Neoplasia
Preti, M., van Seters, M., Sideri, M. G., & van Beurden, M. (2005) · Clinical Obstetrics & Gynecology · doi:10.1097/01.grf.0000181738.37911.03 · Cited by 113
“p16 protein is a cyclin-dependent kinase (cdk) inhibitor, decelerating the cell cycle by inactivating the cdks that phosphorylate the retinoblastoma suppressor gene protein (pRb).(59) It was made clear that there is immunohistochemical expression of p16 in vulvar carcinomas and their precursors.”
BackgroundGruis, N. A., Weaver-Feldhaus, J., Liu, Q., Frye, C., Eeles, R. A., Orlow, I., Lacombe, L., Ponce-Castañeda, V., LIANES, P., & Latres, E. (1995) · Europe PMC (PubMed Central) · Cited by 127
Shi, L., Wang, S., Zangari, M., Xu, H., Cao, T. M., Xu, C., Wu, Y., Xiao, F., Liu, Y., Yang, Y., et al. (2010) · Oncotarget · doi:10.18632/oncotarget.105 · Cited by 129
“Based on these observations, we conclude that while activation of a type D cyclin is an early initiating event, CKS1B over-expression is a progression event; both events are required for the loss of early and late G1- to S-phase cell cycle checkpoints and to establish an aggressive clinical phenotype.”
BackgroundFåhræus, R., & Lane, D. P. (1999) · The EMBO Journal · doi:10.1093/emboj/18.8.2106 · Cited by 113
“…p16INK4 family includes the closely related p15INK4b, p16INK4a, p18INK4c and p19INK4d proteins, which inhibit cdk4 and cdk6 kinase activities through direct interaction with the kinase subunit only (Serrano et al., 1993; Hannon and Beach, 1994; Chan et al., 1995; Hirai et al., 1995).”
BackgroundFogt, F., Vortmeyer, A. O., Goldman, H., Giordano, T. J., Merino, M. J., & Zhuang, Z. (1998) · Human Pathology · doi:10.1016/s0046-8177(98)90222-2 · Cited by 112
Shintani, S., Nakahara, Y., Mihara, M., Ueyama, Y., & Matsumura, T. (2001) · Oral Oncology · doi:10.1016/s1368-8375(00)00142-1 · Cited by 118
Molecular prognostic markers in pancreatic cancer
Ghaneh, P., Kawesha, A., Evans, J. D., & Neoptolemos, J. P. (2002) · Journal of Hepato-Biliary-Pancreatic Surgery · doi:10.1007/s005340200000 · Cited by 125
Inhibitors of DNA methylation in the treatment of hematological malignancies and MDS
Leone, G. G. M., Voso, M. T., Teofili, L., & Lübbert, M. (2003) · Clinical Immunology · doi:10.1016/s1521-6616(03)00207-9 · Cited by 123
Jin, M., Inoue, S., Umemura, T., Moriya, J., ARAKAWA, M., Nagashima, K., & Kato, H. (2001) · Lung Cancer · doi:10.1016/s0169-5002(01)00225-2 · Cited by 112
“The G175405 clone was developed against a full-length recombinant bacterially produced GST-p16 fusion protein [28].”
MethodViallard, J.-F., Lacombe, F., Belloc, F., Pellegrin, J., & Reiffers, J. J. (2001) · Cancer/Radiothérapie · doi:10.1016/s1278-3218(01)00087-7 · Cited by 155
RhoA Stimulates p27Kip Degradation through Its Regulation of Cyclin E/CDK2 Activity
Hu, W., Bellone, C. J., & Baldassare, J. J. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.6.3396 · Cited by 112
Requirement of Cyclin E-Cdk2 Inhibition in p16 INK4a -Mediated Growth Suppression
Jiang, H., Chou, H. S., & Zhu, L. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.9.5284 · Cited by 113
“Unlike the p21-p27 family of cyclin-dependent kinase inhibitors, p16 specifically inhibits cyclin D-dependent kinases in vitro (36).”
BackgroundQin, L. F., & Ng, I. O. (2002) · Cancer Letters · doi:10.1016/s0304-3835(01)00720-0 · Cited by 111
Azechi, H., Nishida, N., Fukuda, Y., Nishimura, T., Minata, M., Katsuma, H., Kuno, M., Ito, T., Komeda, T., Kita, R., et al. (2001) · Oncology · doi:10.1159/000058531 · Cited by 125
“Specifically, one of the CDK inhibitors, p16 (INK4A/MTS-1/CDKN2), is a potent inhibitor of CDK4 and CDK6 and negatively regulates the cyclin D-dependent phosphorylation of the retinoblastoma protein (pRB), thereby inhibiting cell cycle progression from the G1 to S phase [”
Backgroundp16INK4a and the control of cellular proliferative life span
Huschtscha, L. I. (1999) · Carcinogenesis · doi:10.1093/carcin/20.6.921 · Cited by 111
Mutations in the INK4a/ARF Melanoma Susceptibility Locus Functionally Impair p14ARF
Rizos, H., Darmanian, A., Holland, E. A., Mann, G. J., & Kefford, R. F. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m105299200 · Cited by 123
Activation of p53 by oncogenes.
Lowe, S. W. (1999) · Endocrine-related cancer · doi:10.1677/erc.0.0060045 · Cited by 111
“Oncogenes can also induce p53, leading to increased apoptosis or premature senescence (Lowe & Ruley 1993, Hermeking & Eick 1994, Serrano et al. 1997).”
BackgroundReplacement of the p16/CDKN2 gene suppresses human glioma cell growth.
Arap, W., Nishikawa, R., Furnari, F. B., Cavenee, W. K., & Huang, H.-J. S. (1995) · PubMed · Cited by 120
Telomere dysfunction alters the chemotherapeutic profile of transformed cells
Lee, K.-H., Rudolph, K. L., Ju, Y.-J., Greenberg, R. A., Cannizzaro, L., Chin, L., Weiler, S. R., & DePinho, R. A. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.051629198 · Cited by 111
The D-type cyclins and their role in tumorigenesis
Peters, G. (1994) · Journal of Cell Science · doi:10.1242/jcs.1994.supplement_18.13 · Cited by 111
“W ithin the last few months, two more players have entered the arena, the p21 protein that links p53 to the cyclin/Cdk framework (El-Deiry et al., 1993; Harper et al., 1993; Xiong et al., 1993; Noda et al., 1994) and p l6 , a specific inhibitor of Cdk4 (Serrano et al., 1993).”
BackgroundA proximate model for thermal tolerance in ectotherms
Van Der Have, T. M. (2002) · Oikos · doi:10.1034/j.1600-0706.2002.980115.x · Cited by 110
Pannone, G., Santoro, A., Papagerakis, S. M., Muzio, L. L., Rosa, G. D., & Bufo, P. (2011) · Infectious Agents and Cancer · doi:10.1186/1750-9378-6-4 · Cited by 135
“The p16INK4A gene functions as negative regulator of the cell cycle progression through its inhibition of cdk4/6 and subsequent blockage of the cyclindependent phosphorylation of the Rb [59].”
BackgroundEvaluation of alternative methods of cervical cancer screening for resource-poor settings
Denny, L., Kuhn, L., Pollack, A. E., Wainwright, H., & Wright, T. C. (2000) · Cancer · doi:10.1002/1097-0142(20000815)89:4<741::aid-cncr4>3.0.co;2-w · Cited by 250
p21 delays tumor onset by preservation of chromosomal stability
Barboza, J. A., Liu, G., Ju, Z., El-Naggar, A. K., & Lozano, G. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0606343104 · Cited by 110
Simpson, D. J. W., Bicknell, J., McNicol, A. M., Clayton, R. N., & Farrell, W. E. (1999) · PubMed · Cited by 110
Sano, T., Masuda, N., Oyama, T., & Nakajima, T. (2002) · Pathology International · doi:10.1046/j.1440-1827.2002.01359.x · Cited by 117
Marra, D. E., Simoncini, T., & Liao, J. K. (2000) · Circulation · doi:10.1161/01.cir.102.17.2124 · Cited by 110
ARF Function Does Not Require p53 Stabilization or Mdm2 Relocalization
Korgaonkar, C., Zhao, L., Modestou, M., & Quelle, D. E. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.1.196-206.2002 · Cited by 110
“p16 functions in the retinoblastoma (pRb) tumor suppressor pathway (4, 52), whereas ARF protects against aberrant cell growth by activating the p53 tumor suppressor protein (54).”
BackgroundHuman and Yeast Cdk-activating Kinases (CAKs) Display Distinct Substrate Specificities
Kaldis, P., Russo, A. A., Chou, H. S., Pavletich, N. P., & Solomon, M. J. (1998) · Molecular Biology of the Cell · doi:10.1091/mbc.9.9.2545 · Cited by 125
“Unlike the CIP/KIP family proteins, these CKIs bind predominately to the cdk subunit and are specific for cdk4 and cdk6 (Serrano et al., 1993; Guan et al., 1994; Hannon and Beach, 1994; Chan et al., 1995; Hirai et al., 1995). p18 has been shown previously to inhibit phosphorylation by p40MO15 of…”
BackgroundInfluentialRandle, D. H., Zindy, F., Sherr, C. J., & Roussel, M. F. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.171217498 · Cited by 109
To clear, or not to clear (senescent cells)? That is the question
Lujambio, A. (2016) · BioEssays · doi:10.1002/bies.201670910 · Cited by 108
Regulation of phosphatase synthesis in Saccharomyces cerevisiae — a review
Oshima, Y., Ogawa, N., & Harashima, S. (1996) · Gene · doi:10.1016/s0378-1119(96)00425-8 · Cited by 108
Hegde, P. S., Rusnak, D. W., Bertiaux, M., Alligood, K. J., Strum, J. C., Gagnon, R., & Gilmer, T. M. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0399 · Cited by 114
“forms a complex with cyclin D1 (39), hence, it may be”
BackgroundDahlstrand, H. M., Lindquist, D., Björnestål, L., Ohlsson, A., Dalianis, T., Munck‐Wikland, E., & Elmberger, G. (2005) · PubMed · Cited by 108
Wong, D. J., Foster, S. A., Galloway, D. A., & Reid, B. J. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.8.5642 · Cited by 108
“p16 is a cyclin-dependent kinase inhibitor that regulates progression through the G1 phase of the cell cycle by binding and inhibiting cyclin-dependent kinases 4 and 6 (30, 49).”
BackgroundRecovery of function in osteoarthritic chondrocytes induced by p16INK4a-specific siRNA in vitro
Zhou, H. W. (2004) · Rheumatology · doi:10.1093/rheumatology/keh127 · Cited by 108
“Ambion’s siRNA target design online tool was utilized to choose five sequences (Table 1) for targeting human p16INK4a mRNA [ 32 ].”
MethodHuot, T. J., Rowe, J., Harland, M., Drayton, S., Brookes, S., Gooptu, C., Purkis, P., Fried, M., Bataille, V., Hara, E., et al. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.23.8135-8143.2002 · Cited by 107
“The p16 product is the prototype of a family of cyclin-dependent kinase (Cdk) inhibitors that interact directly with Cdk4 and Cdk6, the cyclin D-dependent kinases that initiate the phosphorylation of the retinoblastoma protein pRb (38).”
BackgroundAutophagy and senescence in cancer therapy
Gewirtz, D. A. (2013) · Journal of Cellular Physiology · doi:10.1002/jcp.24420 · Cited by 107
An update on molecular genetics of gastrointestinal stromal tumours
Tornillo, L., & Terracciano, L. (2006) · Journal of Clinical Pathology · doi:10.1136/jcp.2005.031112 · Cited by 116
Consistent expression of the stem cell renewal factor BMI‐1 in primary and metastatic melanoma
Mihic‐Probst, D., Kuster, A., Kilgus, S., Bode‐Lesniewska, B., Ingold‐Heppner, B., Leung, C., Storz, M., Seifert, B., Marino, S., Schraml, P., et al. (2007) · International Journal of Cancer · doi:10.1002/ijc.22891 · Cited by 107
“p16 inhibits the kinase active sites of the cyclin D-dependent kinases Cdk4 and Cdk6 and prevents their associations with cyclins.(7) p16 normally is downregulated upon mitogen stimulation, thus promoting cell cycle progression.”
BackgroundMasumoto, N., Fujii, T., Ishikawa, M., Saito, M., Iwata, T., Fukuchi, T., Susumu, N., Mukai, M., Kubushiro, K., Tsukazaki, K., et al. (2003) · Human Pathology · doi:10.1016/s0046-8177(03)00284-3 · Cited by 119
Silva, J., Silva, J. M., Domínguez, G., García, J. M., Cantos, B., Rodríguez, R., Larrondo, F. J., Provencio, M., España, P., & Bonilla, F. (2003) · The Journal of Pathology · doi:10.1002/path.1297 · Cited by 116
Kuan, C. J., al-Douahji, M., & Shankland, S. J. (1998) · Journal of the American Society of Nephrology · doi:10.1681/asn.v96986 · Cited by 107
P16 UV mutations in human skin epithelial tumors
Soufir, N., Molès, J., Vilmer, C., Moch, C., VEROLA, O., Rivet, J., Tesnière, A., Dubertret, L., & Basset‐Séguin, N. (1999) · Oncogene · doi:10.1038/sj.onc.1202915 · Cited by 124
“Generation of mice lacking speci®cally exon 1 alpha (speci®c of P16INKA) is warranted in order to precise the respective role of both proteins in skin carcinogenesis, as mice previously generated were nullizygous for both genes (Serrano et al., 1996).”
BackgroundInfluentialRelationship between Contact Inhibition and Intranuclear S100c of Normal Human Fibroblasts
Sakaguchi, M., Miyazaki, M., Inoue, Y., Tsuji, T., Kouchi, H., Tanaka, T., Yamada, H., & Namba, M. (2000) · The Journal of Cell Biology · doi:10.1083/jcb.149.6.1193 · Cited by 107
“Interestingly, expression of both p21Waf1 and p16Ink4a, the well known inhibitors of cyclin-dependent kinases (Hunter, 1993; Serrano et al., 1993), was increased in parallel with the nuclear accumulation of S100C.”
BackgroundInoue, K., Wen, R., Rehg, J. E., Adachi, M., Cleveland, J. L., Roussel, M. F., & Sherr, C. J. (2000) · Genes & Development · doi:10.1101/gad.14.14.1797 · Cited by 107
“In contrast, INK4a–ARF- or ARF-null MEFs do not undergo replicative arrest and are transformed by oncogenic Ras without any requirement for collaborating immortalizing oncogenes (Serrano et al. 1996; Kamijo et al. 1997).”
BackgroundMethodHsieh, F. F., Barnett, L. A., Green, W. F., Freedman, K., Matushansky, I., Skoultchi, A. I., & Kelley, L. L. (2000) · Blood · doi:10.1182/blood.v96.8.2746 · Cited by 106
de Magalhães, J. P. (2004) · Experimental Cell Research · doi:10.1016/j.yexcr.2004.07.006 · Cited by 121
Ct, L., Capodieci, P., Osman, I., Fazzari, M. J., Ferrara, J., Scher, H. I., & Cordon‐Cardo, C. (1999) · PubMed · Cited by 111
The cell cycle regulator p27kip1 contributes to growth and differentiation of osteoblasts.
Drissi, H., Hushka, D. R., Aslam, F., Nguyen, Q., Buffone, E., Koff, A., van Wijnen, A. J., Lian, J. B., Stein, J. L., & Stein, G. S. (1999) · PubMed · Cited by 117
Metadata
- Authors
- Serrano, M., Hannon, G. J., & Beach, D.
- Affiliations
- Howard Hughes Medical Institute (US)
- ORCID
- Hannon, Gregory J.
- Venue
- Nature
- Published
- 1993-12
- Volume
- 366
- Issue
- 6456
- Pages
- 704-707
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2066848701
- Cited by
- 3,650
- References
- 22
- Citations by year
- 2026: 36 · 2025: 46 · 2024: 52 · 2023: 66 · 2022: 67 · 2021: 78 · 2020: 64 · 2019: 63 · 2018: 56 · 2017: 70 · 2016: 69 · 2015: 75 · 2014: 52 · 2013: 98 · 2012: 88
- FWCI
- 78.05
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Cold Spring Harbor Laboratory Institutional Repository (Cold Spring Harbor Laboratory) (acceptedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Microtubule and mitosis dynamics
- Keywords
- p16, CDK4, cyclin D, cyclin-dependent kinases, cell cycle regulation, G1 phase, kinase inhibition, retinoblastoma protein, p21, proliferating cell nuclear antigen, feedback regulation, cell proliferation
- MeSH terms
- Amino Acid Sequence, Base Sequence, Carrier Proteins, Cell Cycle, Cloning, Molecular, DNA, Glutathione Transferase, HeLa Cells, Humans, Molecular Sequence Data, Phosphorylation, Proto-Oncogene Proteins, Recombinant Fusion Proteins, Saccharomyces cerevisiae, Oncogene Proteins, Retinoblastoma Protein, Cyclins, Cyclin-Dependent Kinases, Cyclin D1, Cyclin-Dependent Kinase Inhibitor p16, Protein Kinase Inhibitors, Cyclin-Dependent Kinase 4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.